Search > cancer cells
Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting
LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors
REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries
Guest
Virtual reality is finally ready to revolutionize education
Top AI startup news of the week: Jasper, Tome, Imagen AI and more
REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting
Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors
Micronoma to Provide Oncobiota Solution and Company Updates During JPM Life Science Conference Week 2023
Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 American Society of Hematology Annual Meeting
Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
Guest
T-ray technology is moving from sci-fi to mainstream
Plexision launches personalized transplant diagnostic testing in India
LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™
10 top artificial intelligence (AI) applications in healthcare
6 AI companies disrupting healthcare in 2022
NIH Awards AVM Biotechnology SBIR Grant to Study AVM0703 Combined with Standard of Care in Non-Hodgkin’s Lymphoma (NHL) to Improve Complete Response Rates Without Additional Toxicities
Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer
Transform 2022: Announcing the nominees for VentureBeat’s 4th Annual AI Innovation Awards
Community
How AI and human intelligence will beat cancer
AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform
AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703 Against Solid Tumors and Blood Cancers at the 2022 ASCO Annual Meeting
Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors
Bringing digital twins to boost pharmaceutical manufacturing
Code Ocean brings SaaS to computational-research labs, raises $16.5M
Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform
Komodo Health Platform Accelerates Real-World Evidence For Life Sciences
Cleveland Clinic and PathAI partner to identify diseases and offer treatment
Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting
AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes
Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company
Greg Estes interview: What to expect at Nvidia’s GTC event
AVM Biotechnology Expands C-Suite in Anticipation of 2023 Commercialization Efforts
Adrestia Appoints Robert Johnson as Chief Executive Officer
